natszdravНациональное здравоохранениеNational Health Care (Russia)2713-069X2713-0703Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)10.47093/2713-069X.2022.3.1.32-35natszdrav-204Research ArticleПАРАДИГМЫ УПРАВЛЕНИЯ ЗДОРОВЬЕМ В ТРЕХ ВОЗРАСТНЫХ ГРУППАХHEALTH MANAGEMENT PARADIGMS IN THREE AGE GROUPSСравнительный анализ эффективности вакцин против SARS-CoV-2 через 3 месяца после ревакцинацииComparative analysis of the effectiveness of vaccines against SARS-CoV-2 3 months after revaccinationhttps://orcid.org/0000-0001-7201-7395АманнепесовН. К.AmannepesovN. K.

Аманнепесов Нурмухаммет Какабаевич – министр здравоохранения и медицинской промышленности

ул. Арчабил, д. 20, г. Ашгабад, 744036

Nurmuhammet K. Amannepesov – Minister of Health

Archabil str., 20, Ashgabat, 744036

https://orcid.org/0000-0002-4912-1933МавлановК. Х.MavlanovK. H.

Мавланов Кемал Хусаинович – начальник Центра профилактики особо опасных инфекций

ул. О. Аннаева, д. 81, г. Ашгабад, 744036

Kemal Husainovich Mavlanov – Head

O. Annaev str., 81, Ashgabat, 744036

Министерство здравоохранения и медицинской промышленности ТуркменистанаТуркменистанMinistry of Health and Medical Industry of TurkmenistanTurkmenistanЦентр профилактики особо опасных инфекций Государственной санитарно-эпидемиологической службы ТуркменистанаТуркменистанCenter for the Prevention of Highly Infectious Infections of the State Sanitary and Epidemiological ServiceTurkmenistan202207122022313235Copyright © Аманнепесов Н.К., Мавланов К.Х., 20222022Аманнепесов Н.К., Мавланов К.Х.Amannepesov N.K., Mavlanov K.H.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.natszdrav.ru/jour/article/view/204

Начиная с 2021 года в Туркменистане проводится вакцинация населения против новой коронавирусной инфекции (COVID-19). Целью нашей работы явилась сравнительная оценка эффективности вакцин против SARS-CoV-2, используемых при массовой вакцинации населения для выработки популяционного иммунитета.Материалы исследования. В работе использована сыворотка крови 960 человек, вакцинированных «Спутник-лайт» или «БИОвак».Заключение. Через 3 месяца после ревакцинации у 100 % вакцинированных в сыворотке крови сохраняется высокий уровень специфических IgG антител. Сравнительный анализ эффективности двух вакцин, «Спутник-лайт» и «БИОвак», показал, что более длительный иммунный ответ сохраняется после введения вакцины «Спутник-лайт».

Since 2021, Turkmenistan has been vaccinating the population against COVID-19. The aim of the work is a comparative analisis of the effectiveness of vaccines against SARS–CoV-2 used in mass vaccination of the population in the development of population immunity.Research materials. The blood serum of 960 people vaccinated with “Sputnik-lite” or “BIOvac” was used in the work.Conclusion. 3 months after revaccination, 100 % of vaccinated patients have a high level of specific IgG antibodies in their blood serum. A comparative analysis of the effectiveness of two vaccines “Sputnik-lite” and “BIOvac”, showed that a longer immune response persists after the introduction of the vaccine “Sputnik-lite”.

SARS-CoV-2«Спутник-лайт»«БИОвак»возрастгуморальный и клеточный иммунный ответSARS-CoV-2Sputnik-liteBIOvacagehumoral and cellular immune responseReferencesAmannepesov N.K., Mavlanov K., Mamedov M.A., et al. Post-vaccination population immunity against COVID-19 after vaccination with Sputnik-V”. Turkmenistan health care Journal. 2022; 2: 4–12.Amannepesov N.K., Mavlanov K., Mamedov M.A., et al. Post-vaccination population immunity against COVID-19 after vaccination with Sputnik-V”. Turkmenistan health care Journal. 2022; 2: 4–12.Pawlowski C., Lenehan P., Puranik A., et al. FDA-Authorized mRNA COVID-19 Vaccines are Effective Per Real-World Evidence Synthesized Across a Multi-State Health System. medRxiv. 2021; 2(8): 979–992.e8. https://doi.org/10.1016/j.medj.2021.06.007Pawlowski C., Lenehan P., Puranik A., et al. FDA-Authorized mRNA COVID-19 Vaccines are Effective Per Real-World Evidence Synthesized Across a Multi-State Health System. medRxiv. 2021; 2(8): 979–992.e8. https://doi.org/10.1016/j.medj.2021.06.007Thompson M.G., Burgess J.L., Naleway A.L., et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARSCoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers – Eight U.S. Locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(13): 495–500. https://doi.org/10.15585/mmwr.mm7013e3Thompson M.G., Burgess J.L., Naleway A.L., et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARSCoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers – Eight U.S. Locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(13): 495–500. https://doi.org/10.15585/mmwr.mm7013e3Müller L., Andrée M., Moskorz W., et al. Age-Dependent Immune Response to the Biontech/ Pfizer BNT162b2 COVID-19 Vaccination. Clin Infect Dis. 2021; 73(11): 2065–2072. https://doi.org/10.1093/cid/ciab381Müller L., Andrée M., Moskorz W., et al. Age-Dependent Immune Response to the Biontech/ Pfizer BNT162b2 COVID-19 Vaccination. Clin Infect Dis. 2021; 73(11): 2065–2072. https://doi.org/10.1093/cid/ciab381Herzberg J., Fischer B., Lindenkamp C., et al. Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study. Front Immunol. 2022; 13: 839922. https://doi.org/10.3389/fimmu.2022.839922Herzberg J., Fischer B., Lindenkamp C., et al. Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study. Front Immunol. 2022; 13: 839922. https://doi.org/10.3389/fimmu.2022.839922Wei J., Pouwels K.B., Stoesseret N., et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nature Medicine. 2022; 28: 1072–1082. https://doi.org/10.1038/s41591-022-01721-6Wei J., Pouwels K.B., Stoesseret N., et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nature Medicine. 2022; 28: 1072–1082. https://doi.org/10.1038/s41591-022-01721-6Naaber P., Tserel L., Kangro K., et al. Dynamics of Antibody Response to BNT162b2 Vaccine After Six Months: A Longitudinal Prospective Study. Lancet Reg Heal Eur. 2021; 10: 100208. https://doi.org/10.1016/j.lanepe.2021.100208Naaber P., Tserel L., Kangro K., et al. Dynamics of Antibody Response to BNT162b2 Vaccine After Six Months: A Longitudinal Prospective Study. Lancet Reg Heal Eur. 2021; 10: 100208. https://doi.org/10.1016/j.lanepe.2021.100208PouwelsK.B., Pritchard E., Matthews P.C., et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat. Med. 2021; 27(12): 2127-2135. https://doi.org/10.1038/s41591-021-01548-7PouwelsK.B., Pritchard E., Matthews P.C., et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat. Med. 2021; 27(12): 2127-2135. https://doi.org/10.1038/s41591-021-01548-7Parry H., Bruton R., Christine S. Extended interval BNT162b2 vaccination enhances peak antibody generation. npj Vaccines. 2022; 14: 1–5. https://doi.org/10.1038/s41541-022-00432-wParry H., Bruton R., Christine S. Extended interval BNT162b2 vaccination enhances peak antibody generation. npj Vaccines. 2022; 14: 1–5. https://doi.org/10.1038/s41541-022-00432-w

The authors declare that there are no conflicts of interest present.